Literature DB >> 31709736

Increased proportion of time in hybrid closed-loop "Auto Mode" is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump.

Sara H Duffus1, Zain Al Ta'ani2, James C Slaughter3, Kevin D Niswender4,5, Justin M Gregory1.   

Abstract

The Medtronic MiniMed 670G system delivers insulin to patients with type 1 diabetes mellitus (T1DM) using either its hybrid closed-loop (HCL) "Auto Mode" feature or an open-loop mode. In this retrospective, cross-sectional analysis, we quantified the association between time in Auto Mode and both haemoglobin A1c (HbA1c) and time in range (TIR, sensor glucose 70-180 mg/dL) among 96 paediatric and young adult patients with T1DM. The median percentage time in Auto Mode was 38.5% (interquartile range 0%-64%). The percentage time in Auto Mode significantly correlated with HbA1c after adjustment for covariables (β = -0.008, P = 0.014). Each daily 3.4-h increase in Auto Mode time was associated with a 0.1% decrease in HbA1c. Auto Mode time was also correlated with TIR after adjustment for covariables (β = 0.14, P = 0.02): for each daily 8.6-h increase in Auto Mode time, TIR increased by 5%. While Auto Mode use was low, increased time in Auto Mode was associated with a significantly lower HbA1c and increased TIR. These findings emphasize the importance of identifying strategies to improve the ease of use of HCL systems.
© 2019 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31709736      PMCID: PMC7549138          DOI: 10.1111/dom.13912

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  8 in total

1.  Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.

Authors:  Kellee M Miller; Nicole C Foster; Roy W Beck; Richard M Bergenstal; Stephanie N DuBose; Linda A DiMeglio; David M Maahs; William V Tamborlane
Journal:  Diabetes Care       Date:  2015-06       Impact factor: 19.112

2.  Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System.

Authors:  Laurel H Messer; Gregory P Forlenza; Jennifer L Sherr; R Paul Wadwa; Bruce A Buckingham; Stuart A Weinzimer; David M Maahs; Robert H Slover
Journal:  Diabetes Care       Date:  2018-02-14       Impact factor: 19.112

3.  Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch.

Authors:  Michael P Stone; Pratik Agrawal; Xiaoxiao Chen; Margaret Liu; John Shin; Toni L Cordero; Francine R Kaufman
Journal:  Diabetes Technol Ther       Date:  2018-08-30       Impact factor: 6.118

4.  Performance of Medtronic Hybrid Closed-Loop Iterations: Results from a Randomized Trial in Adolescents with Type 1 Diabetes.

Authors:  Martin de Bock; Julie Dart; Michael Hancock; Grant Smith; Elizabeth A Davis; Timothy W Jones
Journal:  Diabetes Technol Ther       Date:  2018-09-11       Impact factor: 6.118

5.  Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.

Authors:  Satish K Garg; Stuart A Weinzimer; William V Tamborlane; Bruce A Buckingham; Bruce W Bode; Timothy S Bailey; Ronald L Brazg; Jacob Ilany; Robert H Slover; Stacey M Anderson; Richard M Bergenstal; Benyamin Grosman; Anirban Roy; Toni L Cordero; John Shin; Scott W Lee; Francine R Kaufman
Journal:  Diabetes Technol Ther       Date:  2017-01-30       Impact factor: 6.118

6.  Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.

Authors:  Gregory P Forlenza; Orit Pinhas-Hamiel; David R Liljenquist; Dorothy I Shulman; Timothy S Bailey; Bruce W Bode; Michael A Wood; Bruce A Buckingham; Kevin B Kaiserman; John Shin; Suiying Huang; Scott W Lee; Francine R Kaufman
Journal:  Diabetes Technol Ther       Date:  2018-12-26       Impact factor: 6.118

7.  Systematic review and meta-analysis of the effectiveness of continuous glucose monitoring (CGM) on glucose control in diabetes.

Authors:  Nalinee Poolsup; Naeti Suksomboon; Aye Mon Kyaw
Journal:  Diabetol Metab Syndr       Date:  2013-07-23       Impact factor: 3.320

8.  Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions.

Authors:  David M Nathan; Margaret Bayless; Patricia Cleary; Saul Genuth; Rose Gubitosi-Klug; John M Lachin; Gayle Lorenzi; Bernard Zinman
Journal:  Diabetes       Date:  2013-12       Impact factor: 9.461

  8 in total
  16 in total

1.  Where Do We Stand with Closed-Loop Systems and Their Challenges?

Authors:  Melanie Jackson; Jessica R Castle
Journal:  Diabetes Technol Ther       Date:  2020-05-22       Impact factor: 6.118

2.  Availability of and access to continuous subcutaneous insulin infusion therapy for adults with type 1 diabetes in Ireland.

Authors:  Katarzyna Anna Gajewska; Regien Biesma; Kathleen Bennett; Seamus Sreenan
Journal:  Acta Diabetol       Date:  2020-03-02       Impact factor: 4.280

3.  Determining the Perception and Willingness of Primary Care Providers to Prescribe Advanced Diabetes Technologies.

Authors:  Alexander O'Donovan; Sean M Oser; Jessica Parascando; Arthur Berg; Donald E Nease; Tamara K Oser
Journal:  J Patient Cent Res Rev       Date:  2021-07-19

4.  A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes.

Authors:  Marc D Breton; Lauren G Kanapka; Roy W Beck; Laya Ekhlaspour; Gregory P Forlenza; Eda Cengiz; Melissa Schoelwer; Katrina J Ruedy; Emily Jost; Lori Carria; Emma Emory; Liana J Hsu; Mary Oliveri; Craig C Kollman; Betsy B Dokken; Stuart A Weinzimer; Mark D DeBoer; Bruce A Buckingham; Daniel Cherñavvsky; R Paul Wadwa
Journal:  N Engl J Med       Date:  2020-08-27       Impact factor: 91.245

5.  Impact of the Hybrid Closed-Loop System on Sleep and Quality of Life in Youth with Type 1 Diabetes and Their Parents.

Authors:  Erin C Cobry; Emily Hamburger; Sarah S Jaser
Journal:  Diabetes Technol Ther       Date:  2020-10-13       Impact factor: 6.118

Review 6.  Felix dies natalis, insulin… ceterum autem censeo "beta is better".

Authors:  Lorenzo Piemonti
Journal:  Acta Diabetol       Date:  2021-05-23       Impact factor: 4.280

7.  A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial.

Authors:  Richard M Bergenstal; Revital Nimri; Roy W Beck; Amy Criego; Lori Laffel; Desmond Schatz; Tadej Battelino; Thomas Danne; Stuart A Weinzimer; Judy Sibayan; Mary L Johnson; Ryan J Bailey; Peter Calhoun; Anders Carlson; Elvira Isganaitis; Rachel Bello; Anastasia Albanese-O'Neill; Klemen Dovc; Torben Biester; Kate Weyman; Korey Hood; Moshe Phillip
Journal:  Lancet       Date:  2021-01-16       Impact factor: 202.731

8.  A Pilot Study of Youth With Type 1 Diabetes Initiating Use of a Hybrid Closed-Loop System While Receiving a Behavioral Economics Intervention.

Authors:  Laura M Nally; Julie Wagner; Jennifer Sherr; Eileen Tichy; Kate Weyman; Meredith K Ginley; Kristyn Zajac; Marcia Desousa; Veronika Shabanova; Nancy M Petry; William V Tamborlane; Michelle Van Name
Journal:  Endocr Pract       Date:  2020-12-15       Impact factor: 3.443

9.  Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes.

Authors:  Laurel H Messer; Cari Berget; Laura Pyle; Timothy Vigers; Erin Cobry; Kimberly A Driscoll; Gregory P Forlenza
Journal:  Diabetes Technol Ther       Date:  2021-06-21       Impact factor: 6.118

10.  Real-World Patient Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology.

Authors:  Jordan E Pinsker; Lars Müller; Alexandra Constantin; Scott Leas; Michelle Manning; Molly McElwee Malloy; Harsimran Singh; Steph Habif
Journal:  Diabetes Technol Ther       Date:  2020-08-26       Impact factor: 6.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.